Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Anand

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
The Journal of Clinical Psychiatry|October 13, 2012
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety studyYona Geffen, Richard Keefe, Jonathan Rabinowitz, et al.
Scientific Reports|September 10, 2024
Implementing Grover's on AES-based AEAD schemesSurajit Mandal, Ravi Anand, Mostafizar Rahman, et al.
BMJ Case Reports|July 9, 2013
Disabling bony ankylosis of hip, knee and axial spine in a neglected patient of ankylosing spondylitisAnkur Nandan Varshney, Nilesh Kumar, Ravi Anand, et al.
The International Journal of Neuropsychopharmacology|June 22, 2023
Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant SchizophreniaRavi Anand, Alessio Turolla, Giovanni Chinellato, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 4, 2003
Impact of study design and patient population on outcomes from cholinesterase inhibitor trialsRavi Anand, Richard Hartman, Hyesung Sohn, et al.
The International Journal of Neuropsychopharmacology|December 11, 2024
Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical TrialRavi Anand, Alessio Turolla, Giovanni Chinellato, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 22, 2002
Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe diseaseSteven G Potki, Ravi Anand, Richard Hartman, et al.
Indian Journal of Anaesthesia|July 25, 2022
Comparison of percutaneous tracheostomy methods in ICU patients: Conventional anatomical landmark method versus ultrasonography method - A randomised controlled trialPankaj Kumar, Sanjeev Kumar, Mumtaz Hussain, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|March 12, 2004
Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced WorseningMurray Raskind, Vinod Kumar, Lisa Malaty, et al.
Therapeutic Advances in Psychopharmacology|January 29, 2026
Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trialsRavi Anand, Alessio Turolla, Giovanni Chinellato, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
The Journal of Clinical Psychiatry|October 13, 2012
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety studyYona Geffen, Richard Keefe, Jonathan Rabinowitz, et al.
Scientific Reports|September 10, 2024
Implementing Grover's on AES-based AEAD schemesSurajit Mandal, Ravi Anand, Mostafizar Rahman, et al.
BMJ Case Reports|July 9, 2013
Disabling bony ankylosis of hip, knee and axial spine in a neglected patient of ankylosing spondylitisAnkur Nandan Varshney, Nilesh Kumar, Ravi Anand, et al.
The International Journal of Neuropsychopharmacology|June 22, 2023
Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant SchizophreniaRavi Anand, Alessio Turolla, Giovanni Chinellato, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 4, 2003
Impact of study design and patient population on outcomes from cholinesterase inhibitor trialsRavi Anand, Richard Hartman, Hyesung Sohn, et al.
The International Journal of Neuropsychopharmacology|December 11, 2024
Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical TrialRavi Anand, Alessio Turolla, Giovanni Chinellato, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 22, 2002
Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe diseaseSteven G Potki, Ravi Anand, Richard Hartman, et al.
Indian Journal of Anaesthesia|July 25, 2022
Comparison of percutaneous tracheostomy methods in ICU patients: Conventional anatomical landmark method versus ultrasonography method - A randomised controlled trialPankaj Kumar, Sanjeev Kumar, Mumtaz Hussain, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|March 12, 2004
Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced WorseningMurray Raskind, Vinod Kumar, Lisa Malaty, et al.
Therapeutic Advances in Psychopharmacology|January 29, 2026
Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trialsRavi Anand, Alessio Turolla, Giovanni Chinellato, et al.
Pageof 5